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Abstract
Cervical cancer screening reduces morbidity and mortality due to cervical cancer. However, there are many factors
that determine the success of any cervical cancer prevention effort: the prevalence of human papillomavirus
infection in general population, the existence of an organized screening program and the corresponding coverage,
the existence and quality of the field and laboratory facilities for screening and diagnostic follow-up, and the
facilities available for treating diagnosed lesions. Monitoring the patient path or “chain of action” for each patient
with an abnormal screening result is of crucial importance. Cost-effectiveness models are widely used by decision-
makers to determine which cervical cancer screening program would maximize health benefits within a given,
usually limited, set of resources. Regardless of their level of sophistication, however, these models cannot replace
empirical evaluations of the effectiveness of screening programs.
Cervical cancer prevention activities need to be monitored and evaluated in each country where they are
introduced to see that they meet performance standards. Policy-makers responsible for allocating resources for
cervical cancer prevention have a duty to allocate resources not only for cervical cancer screening, but also for
screening program surveillance.
Introduction
In the medical field, disease prevention is often consid-
ered a cost-effective alternative to treatment. This state-
ment is especially true for cervical cancer, where late-
stage treatment is expensive and the outcome generally
poor. Indeed, in Norway the 5-year relative survival rate
for patients with late-stage cancer at the time of diagnosis
has remained largely unchanged since 1956, hovering
around 10%. In contrast, the same figure is over 90% for
patients with stage I cancer [1]. Through screening indi-
viduals with asymptomatic preinvasive lesions are identi-
fied and treated to halt the process of cancer
development. These findings imply that early diagnosis
and treatment of cervical disease comprise a powerful
strategy to combat the morbidity and mortality asso-
ciated with cervical cancer. Unfortunately, implementa-
tion of these strategies in some parts of the world is not
always feasible, and recently the International Agency for
Research on Cancer reported that cervical cancer is still
the second most common cancer worldwide, and dispro-
portionately affects low-to-medium-income countries [2].
There is no doubt that cervical cancer screening
reduces the morbidity and mortality due to cervical can-
cer. In order to determine which screening model would
maximize health benefits within a given set of limited
resources, decision makers often use cost-effectiveness
models. During the last decade, results from mathemati-
cal modeling studies have become increasingly impor-
tant in policy-making discussions on whether to
implement human papillomavirus (HPV) vaccination
and/or cervical cancer screening, as well as in the dis-
cussions of different screening tests and regimens [3].
Mathematical modeling is a powerful tool allowing the
comparison of different screening regimens without per-
forming an empirical study.
In the current issue, Shi et al. report on the cost-effec-
tiveness of various cervical cancer screening strategies
using an advanced mathematical model based on the
natural history of cervical cancer. The model was speci-
fically adapted to the Chinese context and applied differ-
ent screening algorithms that are applicable to health
care systems in rural China. Based on their model, the
authors concluded that primary screening with a new
molecular test, careH P Vp e r f o r m sb e t t e rt h a nv i s u a l
Correspondence: mari.nygard@kreftregisteret.no
Fr. Nansens vei 19, P.O. Box 5313 Majorstuen, N-0304, Oslo, Norway
Nygård BMC Cancer 2011, 11:240
http://www.biomedcentral.com/1471-2407/11/240
© 2011 Nygård; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.inspection methods in rural China, particularly if it is
used as part of an orgnized screening programs.
In the current commentary, various aspects of cervical
cancer screening will be discussed, based on the experi-
ences of the Nordic countries.
Discussion
The concept of cervical cancer screening is not new and
dates back to the 1940s. The identification of preinva-
sive cervical lesions is possible through a combination
of Pap smear and histological verification, and allows for
appropriate treatment, i.e., removal or destruction of
preinvasive lesions, which interrupts the natural course
of cervical cancer and stops disease progression. The
challenge lies, however, in making screening and treat-
ment available to all women at risk.
Countries that have implemented cervical cancer
screening, be it opportunistic screening or an organized
program, have observed very different effects on cervical
cancer incidence and mortality [4]. Cervical cancer
screening programs are in place in all of the Nordic
countries, and the existence of population-based cancer
registries, which have been monitoring the incidence
and prevalence of all cancers since the 1950s, provide
the opportunity to observe the effect of cervical cancer
screening in each Nordic country (Figure 1) [5].
Pap smear was integrated into clinical practice in the
Nordic countries in the 1960s. At that time, the age-
standardized incidence rate of cervical cancer was about
15/10
5 in Norway and Finland. Subsequently, these two
otherwise similar countries implemented profoundly dif-
ferent approaches regarding cervical cancer prevention.
Finland introduced an organized screening program at
the beginning of the 1960s. By the 1990s, cervical cancer
incidence in Finland had been reduced to less than 4/
10
5, compared to 13/10
5 in Norway. Indeed, the orga-
nized screening program in Norway wasn’t implemented
until 1995 and cervical cancer incidence has since been
reduced to 9/10
5. In neighboring Denmark, the orga-
nized cervical cancer screening program was also
Figure 1 Age-standarized (world standard population) incidence of (upper graf) and mortality (lower graph) from cervical cancer/10
5
in Denmark, Finland, Iceland, Norway and Sweden in 1945-2008.
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was 31/10
5, twice as high as in the other Nordic coun-
tries. By 2006, cervical cancer incidence in Denmark
h a dd r o p p e dt o1 1 / 1 0
5. These, findings indicate that
both the incidence of and mortality from cervical cancer
have declined remarkably in the Nordic countries fol-
lowing the introduction of organized screening.
However, in 2006 Denmark also reported 3.7 times
more cervical cancer deaths (2.4/10
5) than did Iceland
(0.7/10
5), and Finland had a cervical cancer incidence
rate of 3.9/10
5, which was 2.6 times lower than Den-
mark (10.3/10
5). Clearly the Nordic countries, despite
similar cultural and political backgrounds, and the exis-
tence of publicly funded healthcare systems, have
achieved different levels of success in the prevention of
cervical cancer.
The success of any cervical cancer prevention program
relies on the interplay between the underlying risk fac-
tors that determine the spread of human papillomavirus
infection in general population and the type of screening
program. An organized program is more effective than
an opportunistic program, and most importantly, high
population coverage is a necessary factor for success.
Furthermore, the existence and quality of the field and
laboratory facilities for screening and diagnostic follow-
up, as well as the facilities available for treating diag-
nosed lesions, are key elements of any screening pro-
gram. Monitoring the patient path or “chain of action”
for each patient with an abnormal screening result is of
crucial importance. Only careful monitoring of these
steps allows for the identification of potential shortcom-
ings in the screening program, as well as areas for
improvement [6].
Cervical cancer screening saves lives. Without screen-
ing, the rate of cervical cancer in the Nordic countries
would most likely be higher than it was in the 1960s
due to increased exposure to HPV infection. In Norway,
despite the availability of an affordable and well-func-
tioning health care system, as well as clearly defined
recommendations for screening, follow-up, and treat-
ment, cervical cancer is still a relevant health problem.
Indeed, even after 30 years of opportunistic and 15
years of organized screening, some 300 cervical cancer
cases are still diagnosed in the country every year.
There may be several explanations why organized pro-
grams in different countries do not reduce the burden
of cervical cancer to the same degree. The extent of
screening coverage is generally recognized as one of the
most essential components for success, and coverage is
improved by sending personal invitations to women at
risk. In Norway, about 50% of cervical cancer cases arise
from the 20% of the population who do not attend
screening. The reason for non-attendance varies and
deserves more research, but communication between
health care providers and the target population seems to
play an important role. Adequate communication of the
importance of regular screening and the meaning of test
results motivates women to attend subsequent screening
rounds [7]. Communication is a key component of the
doctor-patient relationship and it is likely that medical
doctors play an integral role in improving patient
knowledge and awareness. This is particularly true in
Norway, where the screener is usually a family doctor or
gynecologist, not a specialized midwife, as in Finland or
Sweden. Educating and motivating the target population
to attend screening is often given low priority by family
doctors/gynecologists due to time constraints. It is also
possible that a medical providers do not offer appropri-
ate explanation, or are not sufficiently receptive to a
woman’s questions, thereby limiting communication
between doctors and women who are to be screened.
One remedy to improve education and motivation for
screening in a Norwegian context is to increase the use
of social media, which can be employed to market
healthy behavior and disseminate health-related
information.
However, it is not only the target screening population
that needs to be educated. A study by the screening regis-
try in Norway investigated clinical compliance with fol-
low-up recommendations by observing how women with
cytological abnormalities were followed-up in real life
situations and comparing it with the recommendations.
The observed adherence to recommendations regarding
diagnostic procedures and treatment was good, provided
that a screening smear indicated the presence of a high-
grade lesion. The recommendations for the follow-up of
low-grade or borderline lesions were often ignored, both
in terms of timing and the type of follow-up test [8].
Such noncompliance results in sub-optimal performance
of the screening regimen and can reduce the overall
effectiveness of the program. Hence it is the extent to
which recommended guidelines are followed in real life
that determines the efficacy of the program, not the mere
presence of formal recommendations.
The type of screening test used also plays an impor-
tant role in cervical cancer screening. In this issue, Shi
and colleagues compared the cost-effectiveness of three
screening tests, HPV DNA testing and two different
visual inspection methods. The authors concluded that
careHPV in regular screening was more cost-effective
than the two visual inspection methods. This finding is
very encouraging, since it demonstrates that an objective
and reliable primary screening test, with an acceptable
performance and price, is now available for use in low-
income countries. As is widely known, the conventional
Pap smear screening method is not the ideal alternative
in many low-resource settings, because the infrastruc-
ture for the test is neither available nor affordable.
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potential advantages compared to Pap smear. First, HPV
DNA testing has a higher sensitivity to detect underlying
preinvasive lesions, as shown by two recently published
randomized controlled trials [9,10]. It can also detect in
situ adenocarcinomas, which often go undetected by
Pap smear. Of equal importance, this in turn means that
there is a low probability that HPV-negative women
harbor preinvasive lesions or cervical cancer, resulting
i nal o n g e rl e a dt i m ec o m p a r e dt oP a ps m e a r .C o n s e -
quently, it is possible to increase the screening interval,
thus reducing the lifetime number of screening episodes
and presumably improving both screening attendance
and recommendation adherence. The reproducibility of
HPV DNA testing is better than that of Pap smear, and
the absence of borderline diagnoses simplifies the fol-
low-up after a positive test. However, the high preva-
lence of high-risk HPV infections among women under
30 years of age suggests that an age-stratified implemen-
tation of primary screening by HPV DNA testing would
be most beneficial, which complicates the overall recom-
mendations. Also, communicating a positive HPV DNA
test result to women can be a challenging and time con-
suming task for the doctor. Sexually transmitted onco-
genic infection is a controversial topic, and cultural and
religious beliefs undoubtedly influence an individual’s
reaction.
Cervical cancer screening has been compared to a
chain that is only as strong as its weakest link. However,
it is often very difficult to identify the weakest link.
Careful auditing of the screening program and monitor-
ing of the key indicators can help to define caveats in
the screening program, which may be country-specific.
Cervical cancer screening performance in the Nordic
countries suggests that the availability of the screening
test and a follow-up regimen alone do not guarantee a
successful program. In addition to high coverage, con-
tinuous quality assurance of performance, both of the
screening test and the follow-up regimen, is required for
the program to fulfill its expectations.
The natural history of cervical cancer has been exten-
sively studied and it is generally accepted that the dis-
ease progresses through preinvasive lesions following
infection with sexually transmitted high-risk HPV types.
This progression can be interrupted by screening. Math-
ematical models mimicking this natural history are
a p p l i e di nd i f f e r e n tp o p u l a t i o n sa sl o n ga st h ek e yv a r i -
ables, as specified by the model, are available. For exam-
ple, results from empirical studies, such as the age-
specific high-risk HPV prevalence or data on sexual
behavior in a given population are used to inform math-
ematical models estimating the natural history of cervi-
cal cancer. Empirical data on screening performance,
however, can only be obtained by monitoring this
performance within a given country. Hence, mathemati-
cal models, regardless of their level of sophistication,
cannot be adequately calibrated without the use of
country-specific screening data. For instance, the effect
of HPV vaccination has been evaluated using mathema-
tical models and the results support the notion that the
vaccines will reduce the cervical cancer burden. These
results reassured the policy makers who chose to allo-
cate resources for vaccination. However, these results
must be confirmed by surveillance studies utilizing
population-based cancer registries, or by empirical
studies.
Conclusion
Modern health care systems are expected to generate the
highest possible overall level of population health within
a given set of resource constraints. Political and ethical
considerations can further influence health care priori-
ties. In this complex situation, findings from cost-effec-
tiveness analyses will continue to impact and inform
decision-making regarding health interventions. It is very
important to emphasize, however, that cost-effectiveness
analyses alone cannot guarantee the success of any pro-
gram. Therefore, in the case of cervical cancer, it could
be argued that the policy makers responsible for allocat-
ing resources for cervical cancer prevention have a duty
to allocate resources both for cancer surveillance and
screening program surveillance. This is particularly
important for low-resource countries.
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